/

/

Seelos Therapeutics Announces Results from Phase II Depression Trial

Thu, Sep 21

Seelos Therapeutics released results from its Phase II study of Major Depressive Disorder & Risk of Suicide. "SLS-002 showed clinically meaningful reductions in symptoms of depression and suicidality" https://t.co/l6xmwj5dhJ

3541

Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide.

Discover